

Notice of the Nominations for the members of the Board of Directors

May 8, 2012---Santen Pharmaceutical Co., Ltd announced today the nominations for the members of the Board of Directors effective on June 20, 2012, subject to approval at the 100th Annual General Meetings of Shareholders and the Board of Directors on June 20, 2012.

Member of the Board of Directors (As of June 20, 2012)

	Name	Current position
Reappointed	Akira Kurokawa	President and CEO
	Toshiaki Nishihata, Ph.D.	Director, Executive Corporate Officer, U.S.and Europe Business, Head of Research and Development Division
	Sadatoshi Furukado	Director, Executive Corporate Officer, Japan and Asia Business Head of Sales and Marketing Division, Prescription Pharmaceuticals
	Noboru Kotani	Director
	Akihiro Okumura	Director
Newly appointed	Takayuki Katayama	Senior Advisor to CEO, Teijin Limited
Retirement	Isao Muramatsu	Director

Noboru Kotani, Akihiro Okumura and Takayuki Katayama are nominees of Outside Directors.

Noboru Kotani and Akihiro Okumura are Independent Officers (as set forth under Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc. and Article 7, Paragraph 1 of the Regulations on Codes of Corporate Conduct of the Osaka Securities Exchange, hereinafter the same shall apply.) and Takayuki Katayama will be also Independent Officer after the approval at the 100th Annual General Meeting of Shareholders and the Board of Directors on June 20, 2012.